Back to the WireInvesting.com
DevelopingInvesting.com ·
Bausch + Lomb stock slips as eye pain drug misses endpoint
Bausch + Lomb shares fell after a headline said an eye pain drug missed its trial endpoint. Only the headline is available, so the trial details and company response are not yet known.
Who is reporting it
- Seeking Alphafirst at Nov 19, 2026, 5:25 PM ESTRead at Seeking Alpha (opens in a new tab)
- Investing.comfirst at Nov 19, 2026, 5:57 PM ESTRead at Investing.com (opens in a new tab)
Story so far
Reported by 2 sources
Bausch + Lomb reported that its post-surgical ocular pain asset failed to meet the main goal of a phase 2 trial, per a Seeking Alpha item. Investing.com later reported the shares slipped on the miss, though that report had only the headline, so trial details and any company response remain unknown.
- Nov 19, 2026, 5:25 PM EST · Seeking AlphaConfirmedBausch + Lomb post-surgical ocular pain asset fails phase 2 main goal
- Nov 19, 2026, 5:57 PM EST · Investing.com · this storyDevelopingBausch + Lomb stock slips as eye pain drug misses endpoint
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.